Release: Release date – 1:16 p.m., Fri – 2 Sep 22
Hyderabad: India’s first indigenous quadrivalent human papillomavirus (HPV) vaccine to prevent cervical cancer will be launched in a few months and made available to people in the affordable Rs.200-400 price range.
For the uninitiated, when cancer starts in the cervix, it’s called cervical cancer. All women are at risk for cervical cancer. It occurs most commonly in women over the age of 30.
Almost all cases of cervical cancer are linked to certain strains of human papillomavirus, a very common virus that is transmitted through sexual contact.
While the body’s immune system usually clears the infection naturally within two years, the virus can linger in some people over time, turning some normal cells into abnormal cells and then cancer, according to the Centers for Disease Control and Prevention (CDC ). .
When cervical cancer is caught early, it is treatable and associated with long survival.
In 2018, an estimated 57,000 women were diagnosed with the disease and it was responsible for 311,000 deaths worldwide. India accounts for about a fifth of the global burden of cervical cancer, with 1.23 lakh cases and around 67,000 deaths per year.
The HPV vaccine protects against the types of HPV that most commonly cause cervical, vaginal and vulvar cancer. It’s given in two doses, and data has shown that the antibodies that develop after both doses are given can last for up to six or seven years.